Sep. 13 at 11:29 AM
$TEM Tempus just notched another regulatory milestone: FDA 510(k) clearance for its upgraded Tempus Pixel platform, which now produces inline T1 & T2 maps—essential for detecting cardiac inflammation & fibrosis across different MRI machines. That cross-scanner compatibility broadens its clinical utility. H.C. Wainwright rewarded the news with a price target bump to
$98 (from
$90) while reiterating a Buy. The stock has responded, hovering near its 52-week high (~
$91–92) with a RS rating around 92—confirmation that institutional momentum is firmly in place.
#RKT Rocket Companies bought Redfin, which means collaging real estate traffic with an equally interest-rate-sensitive mortgage business. Analysts are already hyping rate cuts. BofA upgraded the stock, hiking the target from
$21 to
$24. The case is simple: falling rates potion both purchase & refinance volumes. The Mr. Cooper deal comes with the usual promise of half a billion in “synergies.” Add in
$200M in Redfin synergy fairy dust.
